Physician profile
Hannah Born
NPI 1134627946
$2,210.48
in general payments reported to CMS, 2019-2025
27 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $390 · 2022: $314 · 2023: $504 · 2024: $538 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $564.70 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Teva Pharmaceuticals USA, INC. | $266.29 | 2021-2025 | Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $222.32 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $170.92 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $162.40 | 2021-2025 | |
| Abbvie INC. | $141.73 | 2021-2025 | |
| Biogen, INC. | $79.31 | 2024-2025 | Vumerity, Tysabri |
| Ucb, INC. | $66.64 | 2024 | Rystiggo |
| Jazz Pharmaceuticals INC. | $57.04 | 2024-2025 | |
| Abbott Laboratories | $54.15 | 2021 | |
| Glaxosmithkline, LLC. | $46.69 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $44.29 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.77 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $33.82 | 2022 | |
| Amgen INC. | $29.36 | 2024 | Prolia, Evenity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.32 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $26.72 | 2025 | Veozah |
| Organon LLC | $26.61 | 2022 | |
| Acera Surgical, INC. | $25.00 | 2023 | Restrata Wound Matrix |
| Janssen Biotech, INC. | $23.02 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.13 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.31 | 2021 | |
| Allergan, INC. | $14.46 | 2022 | |
| Emd Serono, INC. | $14.07 | 2023 | Mavenclad |
| Lundbeck LLC | $13.58 | 2022 | |
| Dexcom, INC. | $12.71 | 2023 | Dexcom G6 Transmitter |
| Eisai INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Born listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.